On the afternoon of August 20, 2020, Shenzhen Children’s Hospital sincerely invited Dr. Hu Junyuan, Chairman of Shenzhen Beike Biotechnology Co., Ltd., to give a special lecture on “Clinical Transformation and Application Prospects of Cell Therapy”, focusing on the three cores of “people”, “technology” and “life” to provide an in-depth interpretation of the current cutting-edge fields such as cell therapy, life sciences and biomedical industries. Under the leadership of Dean Ma Xiaopeng, experts, directors, and doctors from multiple departments of the hospital came to the scene to exchange and learn.
Dean Ma said, “Cell therapy technology is currently one of the most popular and promising treatments in the world. Regenerative medicine, represented by stem cells, has achieved a number of research results in recent years. This is for those who also want to embrace future technologies and improve and break through existing medical technologies. For the Shenzhen Children’s Hospital, it has a lot of learning and reference significance. I hope that through this study, the medical staff can bring new ideas and open up ideas, and further strengthen and make breakthroughs in scientific research, so that biomedical technology can bring good news to more children with difficult-to-treat diseases.”
(Speech by Dr. Hu Junyuan, Beike Biotechnology)
Cell therapy technology is the development direction of new human medicine in the 21st century. In recent years, my country has attached great importance to the research and clinical transformation of cell therapy technology. Relevant national authorities and local policies have frequently issued various supports and increased investment in human and financial resources to support stem cell research and clinical transformation. In terms of new stem cell drugs, the “Technical Guiding Principles for Research and Evaluation of Cell Therapy Products (Trial)” and the new drug approval system of “60-day implicit permission for clinical trials” have been formulated, providing new development opportunities for the research, development and application of new stem cell drugs in my country.
In this context, products independently developed by Beike Biotech“Human Umbilical Cord Mesenchymal Stem Cells for Injection in the Treatment of Refractory Systemic Lupus Erythematosus”‘s new drug clinical registration application has been officially accepted by the Review Center of the State Food and Drug Administration. This new stem cell drug is the first domestic stem cell product for the treatment of refractory systemic lupus erythematosus.
Dr. Hu Junyuan mentioned, “Cell therapy technology is developing rapidly. At present, more than 40 stem cell therapy products have been approved globally; and my country’s Food and Drug Administration has accepted more than 10 stem cell products since 2018; there are 108 stem cell clinical research institutions and 12 military hospitals registered with the National Health Commission.”
—— Further reading——
Currently, Beike Biotechnology has cooperated with 5 hospitals to apply for and pass the registration of stem cell clinical research institutions by the National Health Commission, including the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Peking University Shenzhen Hospital, Shenzhen People’s Hospital, the Second Affiliated Hospital of Kunming Medical College, and Hubei Shiyan Taihe Hospital.
It has also accumulated rich clinical experience and clinical research results in the treatment of difficult diseases in children with mesenchymal stem cells. The “Clinical Study on the Safety and Effectiveness of Mesenchymal Stem Cells Derived from Human Umbilical Cord Combined with Modern Rehabilitation in the Treatment of Cerebral Palsy in Children”, submitted in cooperation with Hubei Shiyan Taihe Hospital, was registered as a stem cell clinical research project of the National Health Commission and started in June 2020Clinical study recruitment.
At the same time, Beike Biotechnology also actively participated in this year’s new crown epidemic and wonThe Guangdong Provincial Department of Science and Technology’s “Special Emergency Project for the Prevention and Control of Novel Coronavirus Infection” and the Kunming Municipal Science and Technology Bureau’s “Special Project for the Prevention and Control of Novel Coronavirus Infection Pneumonia”. Led by Beike Biotechnology“Drug Research and Development of Mesenchymal Stem Cells for the Treatment of New Coronavirus Pneumonia” was successfully selected and won the key special recommendation project of “Guangdong Province Science and Technology Assists the Economy 2020”.